Inventor · disambiguated record
John Westwick
Also filed as: WESTWICK JOHN · WESTWICK JOHN K
6 granted patents·16 pending applications·86 citations·filing 2003–2023
84Inventor score
Files withODYSSEY THERA INC13SIGNAL PHARM LLC2WASHINGTON UNIVERSITY ST LOUIS2MICHNICK STEPHEN WILLIAM WATSON1ODYSSEY PHARMACEUTICALS INC1
Top patents by PatentIndex Score
22 records- 0191US7935493B2Protein fragment complementation assays for high-throughput and high-content screeningODYSSEY THERA INC·Filed 2006·Granted May 3, 2011·22 cites·4 claims
- 0288US7062219B2Protein fragment complementation assays for high-throughput and high-content screeningODYSSEY THERA INC·Filed 2004·Granted Jun 13, 2006·32 cites·12 claims
- 0377US7306914B2Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapyODYSSEY THERA INC·Filed 2004·Granted Dec 11, 2007·15 cites·6 claims
- 0477US2024376169A1Compositions and methods for targeted cytokine deliveryWASHINGTON UNIVERSITY ST LOUIS·Filed 2023·Application pending·0 cites
- 0575US7351729B2JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancersSIGNAL PHARM LLC·Filed 2003·Granted Apr 1, 2008·11 cites·8 claims
- 0672US7488583B2Fragment complementation assays for G-protein-coupled receptors and their signaling pathwaysODYSSEY THERA INC·Filed 2004·Granted Feb 10, 2009·6 cites·8 claims
- 0770US11897929B2Compositions and methods for targeted cytokine deliveryWASHINGTON UNIVERSITY ST LOUIS·Filed 2021·Granted Feb 13, 2024·0 cites·5 claims
- 0860US2007149571A1Combination therapy for treating or managing acute myelocytic leukemiaSIGNAL PHARM LLC·Filed 2007·Application pending·0 cites
- 0958US2008145315A1Protein fragment complementation assays in whole animals applications to drug efficacy, adme, cancer biology, immunology, infectious disease and gene therapyODYSSEY PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1054US2008064040A1Monitoring gene silencing and annotating gene function in living cellsODYSSEY THERA INC·Filed 2007·Application pending·0 cites
- 1152US2012208197A1Monitoring gene silencing and annotating gene function in living cellsWATSON MICHNICK STEPHEN WILLIAM·Filed 2011·Application pending·0 cites
- 1251US2012149597A1Protein fragment complementation assays for high-throughput and high-content screeningMICHNICK STEPHEN WILLIAM WATSON·Filed 2011·Application pending·0 cites
- 1350US2004241636A1Monitoring gene silencing and annotating gene function in living cellsFiled 2004·Application pending·0 cites
- 1448US2006009506A1Drugs for the treatment of neoplastic disordersODYSSEY THERA INC·Filed 2005·Application pending·0 cites
- 1547US2010081632A1High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disordersODYSSEY THERA INC·Filed 2009·Application pending·0 cites
- 1646US2006040338A1Pharmacological profiling of drugs with cell-based assaysODYSSEY THERA INC·Filed 2005·Application pending·0 cites
- 1744US2005221280A1Protein-protein interactions for pharmacological profilingODYSSEY THERA INC·Filed 2005·Application pending·0 cites
- 1841US2006094059A1Methods for identifying new drug leads and new therapeutic uses for known drugsODYSSEY THERA INC·Filed 2005·Application pending·0 cites
- 1940US2006160109A1Harnessing network biology to improve drug discoveryODYSSEY THERA INC·Filed 2005·Application pending·0 cites
- 2040US2006094682A1Kinase inhibitors for the treatment of diabetes and obesityODYSSEY THERA INC·Filed 2005·Application pending·0 cites
- 2138US2007212677A1Identifying off-target effects and hidden phenotypes of drugs in human cellsODYSSEY THERA INC·Filed 2006·Application pending·0 cites
- 2237US2004092475A1Organic compoundsFiled 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Westwick files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →